Cargando…
In-vivo dosimetric analysis in total skin electron beam therapy
BACKGROUND AND PURPOSE: Thermoluminescent dosimetry (TLD) is an important element of total skin electron beam therapy (TSEBT). In this study, we compare radiation dose distributions to provide data for dose variation across anatomic sites. MATERIALS AND METHODS: Retrospectively collected data on 85...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7807580/ https://www.ncbi.nlm.nih.gov/pubmed/33458390 http://dx.doi.org/10.1016/j.phro.2018.05.002 |
_version_ | 1783636771444097024 |
---|---|
author | Elsayad, Khaled Moustakis, Christos Simonsen, Manuela Bäcker, Dagmar Haverkamp, Uwe Eich, Hans Theodor |
author_facet | Elsayad, Khaled Moustakis, Christos Simonsen, Manuela Bäcker, Dagmar Haverkamp, Uwe Eich, Hans Theodor |
author_sort | Elsayad, Khaled |
collection | PubMed |
description | BACKGROUND AND PURPOSE: Thermoluminescent dosimetry (TLD) is an important element of total skin electron beam therapy (TSEBT). In this study, we compare radiation dose distributions to provide data for dose variation across anatomic sites. MATERIALS AND METHODS: Retrospectively collected data on 85 patients with cutaneous lymphoma or leukemia underwent TSEBT were reviewed. Patients were irradiated on two linear accelerators, in one of two positions (standing, n = 77; reclined, n = 8) and 1830 in vivo TLD measurements were obtained for various locations on 76 patients. RESULTS: The TLD results showed that the two TSEBT techniques were dosimetrically heterogeneous. At several sites, the dose administered correlated with height, weight, and gender. After the first TLD measurement, fourteen patients (18%) required MU modification, with a mean 10% reduction (range, −25 to +35). Individual TLD results allowed us to customize the boost treatment for each patient. For patients who were evaluated in the standing position, the most common underdosed sites were the axilla, perineum/perianal folds, and soles (each receiving 69%, 20%, and 34% of the prescribed dose, respectively). For patients evaluated in a reclining position, surface dose distribution was more heterogeneous. The sites underdosed most commonly were the axilla and perineum/perianal folds (receiving less than one third of prescribed dose). Significant variables were detected with model building. CONCLUSION: TLD measurements were integral to quality assurance for TSEBT. Dose distribution at several anatomical sites correlated significantly with gender, height, and weight of the treated individual and might be predicted. |
format | Online Article Text |
id | pubmed-7807580 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-78075802021-01-14 In-vivo dosimetric analysis in total skin electron beam therapy Elsayad, Khaled Moustakis, Christos Simonsen, Manuela Bäcker, Dagmar Haverkamp, Uwe Eich, Hans Theodor Phys Imaging Radiat Oncol Original Research Article BACKGROUND AND PURPOSE: Thermoluminescent dosimetry (TLD) is an important element of total skin electron beam therapy (TSEBT). In this study, we compare radiation dose distributions to provide data for dose variation across anatomic sites. MATERIALS AND METHODS: Retrospectively collected data on 85 patients with cutaneous lymphoma or leukemia underwent TSEBT were reviewed. Patients were irradiated on two linear accelerators, in one of two positions (standing, n = 77; reclined, n = 8) and 1830 in vivo TLD measurements were obtained for various locations on 76 patients. RESULTS: The TLD results showed that the two TSEBT techniques were dosimetrically heterogeneous. At several sites, the dose administered correlated with height, weight, and gender. After the first TLD measurement, fourteen patients (18%) required MU modification, with a mean 10% reduction (range, −25 to +35). Individual TLD results allowed us to customize the boost treatment for each patient. For patients who were evaluated in the standing position, the most common underdosed sites were the axilla, perineum/perianal folds, and soles (each receiving 69%, 20%, and 34% of the prescribed dose, respectively). For patients evaluated in a reclining position, surface dose distribution was more heterogeneous. The sites underdosed most commonly were the axilla and perineum/perianal folds (receiving less than one third of prescribed dose). Significant variables were detected with model building. CONCLUSION: TLD measurements were integral to quality assurance for TSEBT. Dose distribution at several anatomical sites correlated significantly with gender, height, and weight of the treated individual and might be predicted. Elsevier 2018-05-19 /pmc/articles/PMC7807580/ /pubmed/33458390 http://dx.doi.org/10.1016/j.phro.2018.05.002 Text en © 2018 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Research Article Elsayad, Khaled Moustakis, Christos Simonsen, Manuela Bäcker, Dagmar Haverkamp, Uwe Eich, Hans Theodor In-vivo dosimetric analysis in total skin electron beam therapy |
title | In-vivo dosimetric analysis in total skin electron beam therapy |
title_full | In-vivo dosimetric analysis in total skin electron beam therapy |
title_fullStr | In-vivo dosimetric analysis in total skin electron beam therapy |
title_full_unstemmed | In-vivo dosimetric analysis in total skin electron beam therapy |
title_short | In-vivo dosimetric analysis in total skin electron beam therapy |
title_sort | in-vivo dosimetric analysis in total skin electron beam therapy |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7807580/ https://www.ncbi.nlm.nih.gov/pubmed/33458390 http://dx.doi.org/10.1016/j.phro.2018.05.002 |
work_keys_str_mv | AT elsayadkhaled invivodosimetricanalysisintotalskinelectronbeamtherapy AT moustakischristos invivodosimetricanalysisintotalskinelectronbeamtherapy AT simonsenmanuela invivodosimetricanalysisintotalskinelectronbeamtherapy AT backerdagmar invivodosimetricanalysisintotalskinelectronbeamtherapy AT haverkampuwe invivodosimetricanalysisintotalskinelectronbeamtherapy AT eichhanstheodor invivodosimetricanalysisintotalskinelectronbeamtherapy |